A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas

NCT07444619 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Soft Tissue Sarcomas

Interventions

DRUG: Pazopanib
DRUG: Trabectedin
DRUG: Ipilimumab
DRUG: Nivolumab

Sponsor

M.D. Anderson Cancer Center